{
    "clinical_study": {
        "@rank": "164641", 
        "arm_group": [
            {
                "arm_group_label": "Low dose epidural morphine", 
                "arm_group_type": "Active Comparator", 
                "description": "One dose of 1.25 mg epidural morphine"
            }, 
            {
                "arm_group_label": "High dose epidural morphine", 
                "arm_group_type": "Active Comparator", 
                "description": "One dose of 2.5 mg epidural morphine"
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One dose of 10 ml saline administered through an epidural catheter"
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot study intends to establish the efficacy of 2 different doses of epidural morphine\n      for pain management after perineal trauma when using multimodal analgesia as well as the\n      feasibility of conducting a larger randomized clinical trial. Women with traumatic vaginal\n      delivery will be randomized into 3 groups with 10 patients each and receive 2.5 mg epidural\n      morphine, 1.25 mg epidural morphine, or epidural saline. The primary outcome is total opioid\n      consumption for breakthrough pain in the first 24 hours."
        }, 
        "brief_title": "Epidural Morphine for Analgesia After Traumatic Vaginal Delivery", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Traumatic Vaginal Delivery", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is 18 years or older\n\n          -  The patient is ASA 1-3\n\n          -  Gestation 37-42 weeks\n\n          -  The patient had a vaginal delivery\n\n          -  The patient received epidural analgesia for labor and delivery\n\n        Exclusion Criteria:\n\n          -  The patient has refused to participate\n\n          -  The patient cannot give informed consent\n\n          -  The investigator has significant concerns for maternal or neonatal welfare\n\n          -  The patient has a history of allergy to opioids\n\n          -  The patient has a history of chronic opioid consumption\n\n          -  The patient has a history of narcotic abuse\n\n          -  The patient has an allergy to local anesthetics\n\n          -  The patient has a contraindication to taking NSAIDs or acetaminophen\n\n          -  The patient received combined spinal-epidural analgesia\n\n          -  The patient has a history of chronic pain"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689597", 
            "org_study_id": "18501"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low dose epidural morphine", 
                    "High dose epidural morphine"
                ], 
                "description": "Comparison of different dosages of drug", 
                "intervention_name": "Morphine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Morphine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 20, 2012", 
        "number_of_arms": "3", 
        "official_title": "Efficacy of Two Doses of Epidural Morphine for Analgesia After Traumatic Vaginal Delivery: a Randomized, Double Blinded, Placebo-controlled Pilot Study", 
        "overall_official": {
            "affiliation": "University of Western Ontario, Canada", 
            "last_name": "Sudha I Singh, MD FRCPC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Total breakthrough opioid consumption", 
            "safety_issue": "No", 
            "time_frame": "First 24 hours after delivery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689597"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lawson Health Research Institute", 
            "investigator_full_name": "Indu Singh", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pain scores at rest", 
                "safety_issue": "No", 
                "time_frame": "At 6, 12, 24, and 36 h after delivery"
            }, 
            {
                "measure": "Pain scores with movement", 
                "safety_issue": "No", 
                "time_frame": "At 6, 12, 24, and 36 h after delivery"
            }, 
            {
                "measure": "Severity of nausea/vomiting", 
                "safety_issue": "No", 
                "time_frame": "At 6, 12, 24, and 36 h after delivery"
            }, 
            {
                "measure": "Severity of pruritis", 
                "safety_issue": "No", 
                "time_frame": "At 6, 12, 24, and 36 h after delivery"
            }, 
            {
                "measure": "Severity of sedation", 
                "safety_issue": "No", 
                "time_frame": "At 6, 12, 24, and 36 h after delivery"
            }, 
            {
                "measure": "Time to first request for additional analgesia", 
                "safety_issue": "No", 
                "time_frame": "First 36 h after delivery"
            }, 
            {
                "measure": "Patient satisfaction with pain control", 
                "safety_issue": "No", 
                "time_frame": "At 24 and 36 h after delivery"
            }, 
            {
                "measure": "Quality of Recovery", 
                "safety_issue": "No", 
                "time_frame": "At 24 and  36 h after delivery"
            }, 
            {
                "measure": "Antiemetic consumption", 
                "safety_issue": "No", 
                "time_frame": "First 36 h after delivery"
            }, 
            {
                "measure": "Antipruritic medication consumption", 
                "safety_issue": "No", 
                "time_frame": "First 36 h after delivery"
            }, 
            {
                "measure": "Total opioid consumption", 
                "safety_issue": "No", 
                "time_frame": "First 36 h after delivery"
            }
        ], 
        "source": "Lawson Health Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lawson Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}